Esperion Therapeutics ESPR Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's total equity?
- Esperion Therapeutics (ESPR) reported total equity of -$307.93M in Q1 2026.
- How has Esperion Therapeutics's total equity changed year-over-year?
- Esperion Therapeutics's total equity increased by 27.8% year-over-year, from -$426.21M to -$307.93M.
- What is the long-term trend for Esperion Therapeutics's total equity?
- Over 5 years (2020 to 2025), Esperion Therapeutics's total equity has grown at a 25.7% compound annual growth rate (CAGR), from -$96.13M to -$301.97M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.